Contact
Hand us the ten things you just shipped. We will show you what your own R&D missed.
RocSite is an independent discovery engine. A rare fusion of world data and adversarial method, pointed at your own recent work: a new drug, a released clinical model, a flagship paper, a pipeline. It surfaces the novel, valuable, and dangerous signals that siloed teams and the published literature cannot see. Pre-Submission accepted January 2026. 286,510 patients, pre-registered, null result published.
RocSite is an orchestrated discovery pipeline. It generates hypotheses from 51 million documents, tests them for cause versus coincidence across multiple national health-system datasets, cross-checks the survivors against real-world adverse-event data and medical imaging, and filters out any claim built on retracted science. Then a council of specialist reviewers tries to destroy each finding that remains. Every step is pre-registered and cryptographically signed, so a skeptic can verify the entire chain independently.
What survives is a screening hypothesis for your experts, with the evidence attached. Not a conclusion. Not a diagnosis. Nothing on this page is a diagnostic device.
Point us at what you have already released to the public. We run the engine and hand back real, checkable findings with the signed evidence chain, so you can verify every one yourself. Only then do you decide whether to point it at your full pipeline, on your own data, in your own environment. Your data never leaves your control. We never sell data.
The method has already done this in the open. Our pre-registered sepsis transportability study pooled 286,510 ICU patients and found nothing. Stratified by hospital size, a real effect emerged that standard pooled validation hid. The whole chain is pre-registered and cryptographically signed, and we published it with the null headline intact. That is the engine finding what pooled analysis misses, and reporting honestly when the answer is no.
And to be clear about what you are buying: the first run is the demonstration, not the product. The product is the capability. This engine, standing against your pipeline, in your environment, under your control, surfacing what your own teams cannot see before someone outside your walls does.
The same validation core underneath, tuned per industry. Find what disagrees with the model, and prove when you found it.
An LLM that hallucinates a number from an earnings call doesn’t just embarrass an analyst; it moves money. The architecture validates AI-extracted claims against source transcripts and regulator filings (EDGAR-class sources), with every check signed, chained and auditable.
Felarity for finance ↗ICH Triage detects intracranial hemorrhage on head CT, offline, no PHI transmitted. FDA Pre-Submission accepted January 2026, Class II SaMD pathway. AI Governor adversarially validates clinical AI across 21 modalities.
ICH Triage → AI Governor →Cross-session contradiction detection catches the second deposition’s conflict with the first, with a chain of custody built for Daubert scrutiny.
roclarity ↗ Deposition console ↗Felarity is the Corporate AI OS: every answer cites its evidence from your own record, and when it doesn’t know, it says so.
Felarity ↗Caliper validates drug-safety claims against FAERS with regulatory-standard disproportionality math; Discovery pre-registers hypotheses before data access.
Discovery & Caliper ↗Independent adversarial validation. AI outputs are compared against established, domain-appropriate ground truth (peer-reviewed clinical instruments, regulator filings, the sworn record), with cryptographic attestation of every comparison. The point is to disprove the model on cases that matter, not to celebrate it on cases that don’t.
Proven on the FDA track. We proved the method where the bar is highest. ICH Triage is an offline AI device for detecting intracranial hemorrhage in head CT scans. It runs on hospital infrastructure with no PHI transmitted. FDA Pre-Submission was accepted in January 2026 on the Class II SaMD pathway.
Peer-reviewable methodology. The sepsis falsification study (286,510 ICU patients across MIMIC-IV and eICU-CRD) was pre-registered before any data access. The hypothesis was locked. The primary cohort returned a null result. We published it anyway. Read the study →
Every product sits on the same foundation. The industry changes; the discipline does not.
ICH Triage is an offline device for detecting intracranial hemorrhage in head CT, Class II SaMD pathway, Pre-Submission accepted January 2026. AI Governor independently validates clinical AI across 21 modalities (19 deterministic scoring specialists plus chest X-ray and head CT vision pipelines). AI Governor is not a medical device.
The Corporate AI OS. Evidence-grounded answers drawn from your own record, contradiction detection across sessions, and attestation chains over the result. Finance and legal verticals build on the same core.
felarity.com ↗Forensic AI for legal work: contradiction surfacing across the sworn record, with a chain of custody designed to survive Daubert scrutiny.
roclarity.com ↗Discovery generates hypotheses across large clinical datasets and pre-registers them before data access. Caliper validates drug-safety claims against FAERS using regulatory-standard disproportionality math (PRR with confidence intervals), then signs and chains the result to a public ledger.
Your safety, discovery, imaging, real-world-evidence, and literature teams do not share one pipeline. No internal team can hunt for its own product’s failures without bias. And almost nobody has clinical data from multiple national health systems, adverse-event data, medical imaging, and the full literature fused under one pre-registered method. Independence, plus that rare fused data combination, plus adversarial rigor: that is what stays hard to reach, even with a large budget.
We validate models we didn’t build. A verdict is only worth the distance between the checker and the checked.
Finance pilots run under NDA or on synthetic data.
We built validation rigorous enough for the FDA, then generalized it. Three revenue-bearing product lines, published research, patent pending. Deck and data room on request.
Bring us your recent releases and we will show you what is inside them. One email starts it.
